NuVasive CEO purchases stock worth $492k — 5 things to note

Written by Mary Rechtoris | June 11, 2015 | Print  |

On June 8, NuVasive CEO acquired 10,000 shares of NuVasive stock totaling $492,600.00 for the entire transaction.

Here are five quick facts:


1. The stock has a 50-day moving average of $47 and a market cap of $2.39 billion.


2. NuVasive, a medical device company, reported earnings of $0.30 earnings per share last quarter, surpassing analysts' estimate by $0.09.


3. NuVasive had revenue of $192.40 million last quarter with analysts' consensus estimate being $189.30 million.


4. Analysts at Goldman Sachs downgraded NuVasive shares by stating it as a "neutral" rating as opposed to its former "buy" rating.


5. Despite Goldaman Sach's rating, the company still has an average rating of "buy" and an average price of $53.07.


For more device-related news:
8 trends in the North American neurosurgery market
Is the Zimmer-Biomet closed merger finally around the corner? 5 things to know
Centinel Spine reaches 20k milestone with STALIF C — 5 key notes

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers